Embody vs PeptidesRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Embody
Best for lowest first-month entry pricing on compounded GLP-1sStarting at $99/mo
PeptidesRx
Best for patients prioritizing regulatory compliance in the compounded spaceStarting at $169/mo
Side-by-Side Comparison
| Feature | Embody | PeptidesRx |
|---|---|---|
| Overall Score | ✓8.5/10 | 7.9/10 |
| Starting Price | ✓$99/mo | $169/mo |
| Editorial Rating | ✓4.3 ★ /5 | 4 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Embody
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
PeptidesRx
Pros
- ✓Compliance-focused positioning vs gray-market vendors
- ✓Board-certified medical director
- ✓Transparent pricing with no surprise fees
- ✓Real prescriptions, not research-chemical channel
Cons
- ✗Smaller scale than Henry Meds or Hims
- ✗Wide peptide menu may distract from GLP-1 focus
Our Verdict
Embody edges out PeptidesRx with a higher overall score of 8.5/10 and is particularly strong for lowest first-month entry pricing on compounded GLP-1s. PeptidesRx remains a solid alternative, especially if you're looking for patients prioritizing regulatory compliance in the compounded space.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.